These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 8086668)
1. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Mattern MR; Hofmann GA; Polsky RM; Funk LR; McCabe FL; Johnson RK Oncol Res; 1993; 5(12):467-74. PubMed ID: 8086668 [TBL] [Abstract][Full Text] [Related]
2. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Hendricks CB; Rowinsky EK; Grochow LB; Donehower RC; Kaufmann SH Cancer Res; 1992 Apr; 52(8):2268-78. PubMed ID: 1348448 [TBL] [Abstract][Full Text] [Related]
3. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Hoki Y; Fujimori A; Pommier Y Cancer Chemother Pharmacol; 1997; 40(5):433-8. PubMed ID: 9272121 [TBL] [Abstract][Full Text] [Related]
4. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Mattern MR; Hofmann GA; McCabe FL; Johnson RK Cancer Res; 1991 Nov; 51(21):5813-6. PubMed ID: 1657371 [TBL] [Abstract][Full Text] [Related]
5. Camptothecin analogues with enhanced antitumor activity at acidic pH. Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623 [TBL] [Abstract][Full Text] [Related]
6. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Yang CJ; Horton JK; Cowan KH; Schneider E Cancer Res; 1995 Sep; 55(18):4004-9. PubMed ID: 7664272 [TBL] [Abstract][Full Text] [Related]
7. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765 [TBL] [Abstract][Full Text] [Related]
8. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Kawato Y; Aonuma M; Hirota Y; Kuga H; Sato K Cancer Res; 1991 Aug; 51(16):4187-91. PubMed ID: 1651156 [TBL] [Abstract][Full Text] [Related]
9. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302 [TBL] [Abstract][Full Text] [Related]
10. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443 [TBL] [Abstract][Full Text] [Related]
11. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Ma J; Maliepaard M; Nooter K; Loos WJ; Kolker HJ; Verweij J; Stoter G; Schellens JH Br J Cancer; 1998 May; 77(10):1645-52. PubMed ID: 9635842 [TBL] [Abstract][Full Text] [Related]
12. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations. Urasaki Y; Takebayashi Y; Pommier Y Cancer Res; 2000 Dec; 60(23):6577-80. PubMed ID: 11118036 [TBL] [Abstract][Full Text] [Related]
13. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Sorensen M; Sehested M; Jensen PB Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225 [TBL] [Abstract][Full Text] [Related]
15. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Tanizawa A; Pommier Y Cancer Res; 1992 Apr; 52(7):1848-54. PubMed ID: 1312902 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues. Chambers SK; Hait WN; Kacinski BM; Keyes SR; Handschumacher RE Cancer Res; 1989 Nov; 49(22):6275-9. PubMed ID: 2804973 [TBL] [Abstract][Full Text] [Related]
17. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. Tanizawa A; Fujimori A; Fujimori Y; Pommier Y J Natl Cancer Inst; 1994 Jun; 86(11):836-42. PubMed ID: 8182764 [TBL] [Abstract][Full Text] [Related]
18. Cytoskeletal interference - A new mode of action for the anticancer drugs camptothecin and topotecan. Wang X; Tanaka M; Krstin S; Peixoto HS; Moura CCM; Wink M Eur J Pharmacol; 2016 Oct; 789():265-274. PubMed ID: 27474470 [TBL] [Abstract][Full Text] [Related]
19. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731 [TBL] [Abstract][Full Text] [Related]
20. The current status of camptothecin analogues as antitumor agents. Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]